BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jan 10, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Omapro omacetaxine mepesuccinate regulatory update

ChemGenex withdrew an MAA for omacetaxine for Gleevec-resistant chronic myelogenous leukemia (CML) in patients who have the BCR-ABL T315I mutation. The company now plans to submit a new MAA in 2H11...

Read the full 134 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >